- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Hossein Kazemi Discusses De-escalating Treatment Tools for Patients With Multiple Myeloma
M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care, identifies key tools in de-escalating treatment for patients with multiple myeloma.
M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care, speaks about some of the most used tools in patient assessment for de-escalation treatment for patients with multiple myeloma.
Transcript
What are some of the tools most frequently used to assess if a patient with multiple myeloma is eligible for de-escalation treatment?
Currently there is really no one factor yet that makes us decide if a patient is a good candidate for treatment de-escalation or not, it depends on multiple things. First of all, how long the patient has been on treatment, how the patient is doing on treatment.
Some people are on maintenance and it's not any burden to them. Some patients each clinic visit keep asking you, they cannot wait to go off treatments, basically it impacts their quality of life, etc.
And also, very importantly, how good of a response they have had, how deep the response is. And these things really assist us by MRD testing or measurable disease testing. Basically, there are different platforms, but the one that really is being used most likely in the United States is NGS testing. And we are collaborating with Adaptive, which provides us with the platform to test for us, in our patients.
California Aims for Equity by Redefining Cancer Care
December 8th 2023Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Real-World Data Show Poor Outcomes Among Patients With ACS and Blood Cancers
December 8th 2023A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.
Read More
